Cytokinetics CYTK Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's net income?
- Cytokinetics (CYTK) reported net income of -$206.03M in Q1 2026.
- How has Cytokinetics's net income changed year-over-year?
- Cytokinetics's net income decreased by 27.7% year-over-year, from -$161.38M to -$206.03M.
- What is the long-term trend for Cytokinetics's net income?
- Over 4 years (2021 to 2025), Cytokinetics's net income has grown at a 38.2% compound annual growth rate (CAGR), from -$215.31M to -$784.96M.
- What does net income mean?
- The total profit or loss remaining after all expenses are subtracted from revenue.
- How do you interpret net income?
- An increase signals improved profitability or reduced losses, while a decrease signals declining margins or higher operational costs.
- How does net income compare across companies?
- Standard across all industries; typically negative for early-stage drug developers.